Augustine Asset Management’s Novartis NVS Stock Holding History

Augustine Asset Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-11,015	Closed	-$797K	–	78
2018 Q1	$797K	Buy	11,015 +4,922	+81%	+$375K	0.46%	56
2017 Q4	$458K	Sell	6,093 -3,462	-36%	-$261K	0.26%	60
2017 Q3	$735K	Buy	+9,555	New	+$722K	0.47%	50

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Augustine Asset Management's NVS Position: Q2 2018 in Review

Augustine Asset Management sold out of Novartis (NVS) in Q2 2018, closing a stake of 11,015 shares — an estimated $797K sold.

Augustine Asset Management first reported a position in NVS in Q3 2017 and held it in 3 quarters. The position peaked at $797K in Q1 2018. 987 funds tracked by Wall St. Rank hold NVS as of Q2 2018.

Augustine Asset Management reported no remaining Novartis position as of Q2 2018 after selling out during the quarter.
Augustine Asset Management sold 11,015 Novartis shares in Q2 2018, an estimated $797K.
Augustine Asset Management first reported a position in Novartis in Q3 2017 and held it in 3 quarters.
Augustine Asset Management's Novartis position peaked at $797K in Q1 2018.
987 funds tracked by Wall St. Rank held Novartis as of Q2 2018.

Based on Augustine Asset Management's 13F filing for Q2 2018, filed 12 Jul 2018.